# OnCo record duvelisib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/duvelisib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "duvelisib" ;
  schema:name "Duvelisib"@en ;
  schema:description "A dual PI3K inhibitor for relapsed CLL whose survival data raised FDA concern; use is now limited to late lines."@en ;
  schema:url <https://onco.cc/drugs/duvelisib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Duvelisib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27077129> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=duvelisib> ;
  onco:status "approved" ;
  onco:tag "gap-fill" ;
  onco:modality "Small-molecule PI3Kδ/γ inhibitor" ;
  schema:alternateName "Copiktra" ;
  onco:approval "US 2018: Relapsed/refractory CLL/SLL after ≥2 prior therapies; FL (withdrawn 2021)", "EU 2021: CLL after ≥2 therapies; FL after ≥2 therapies" ;
  onco:acceleratedApproval "US 2018-09-24: Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least 2 prior systemic therapies" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/pik3ca/> ;
  onco:companies <https://onco.cc/companies/infinity-pharmaceuticals/> ;
  onco:pathways <https://onco.cc/pathways/pi3k-akt-mtor/> ;
  onco:trials <https://onco.cc/trials/nct06522737/> .